A small study of Inovio Biomedical’s Hepatitis C vaccine employing electric pulse technology yields encouraging safety data.
Inovio Biomedical’s hepatitis C vaccine progresses
Philadelphia Business Journal – by John George Staff Writer
Monday, November 30, 2009
Inovio Biomedical Corp. said Monday its drug-development partner Tripep completed a phase-I clinical study of its hepatitis C DNA vaccine.
Tripep of Sweden tested its vaccine, called ChronVac-C and delivered using Inovio’s electroporation technology, in 12 patients with positive results.
Continue reading the entire article:
http://philadelphia.bizjournals.com/philadelphia/stories/2009/11/30/daily1.html